PDF(1706 KB)
Cost-effectiveness analysis of dacomitinib versus gefitinib in first line treatment of advanced non-small cell lung cancer with epidermal growth factor receptor mutation
HONG Wang-long, XIA Yi-miao, SU Guang-quan, ZHANG Xu-dong, FANG Ping-ping, ZHU Wen-tao, ZHENG Miao-miao, MA Guo-qiang, SHEN Ai-zong
Chinese Journal of Hospital Pharmacy ›› 2023, Vol. 43 ›› Issue (8) : 925-930.
PDF(1706 KB)
PDF(1706 KB)
Cost-effectiveness analysis of dacomitinib versus gefitinib in first line treatment of advanced non-small cell lung cancer with epidermal growth factor receptor mutation
({{custom_author.role_en}}), {{javascript:window.custom_author_en_index++;}}| {{custom_ref.label}} |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
/
| 〈 |
|
〉 |
